

Scale-up of a Perfusion-Based AAV Manufacturing Process

Authors: [Becci Gunn](#), Ashley Vey, Florian Dziopa




MSAT Upstream Process Development, MeiraGTx, London, UK

Introduction

MeiraGTx's perfusion-based adeno-associated viral vector (AAV) manufacturing platform process was previously optimized and modulated through the choice of transfection reagents, AAV production enhancers, and transfection parameters, in 250mL stirred tank reactors.

The work presented here shows the scale-up of our perfusion-enhanced AAV process to the 40L production scale, with a focus on the translation of perfusion parameters.

Perfusion-Enhanced HEK293 Triple-Transfection Platform



Up to 2.2X Increase in VG titre

Improved Quality Profile

33-50% Reduction in pDNA Usage

Up to 2.2X Reduction in COGs per Dose

Methods

Perfusion Culture


Cells were recirculated through a hollow fibre filter at constant flow rate using a centrifugal pump (Levitronix, Switzerland). A total of 2 vessel volumes of medium was perfused over ~10h prior to transfection. HEK293 cells were transfected at a target VCD range of $4.5\text{--}5.0 \times 10^6$ VC/mL. Product was harvested 3 days post-TFX. Harvest culture was clarified, then purified via affinity chromatography (AAVX).

Analytics

Viral genome (VG) titre and residual pDNA (KanR) were determined in lysate using qPCR. % full capsids and hcDNA were measured in AAVX eluate by AUC and qPCR, respectively.



Scale-Up to 40L Manufacturing Scale




Scalable Perfusion Process

VG Titre in Line with Bench-Scale


AAV Quality Profile Maintained at 40L Manufacturing-Scale

Perfusion Filter Scale-Up




- » With 15cm² filter at 250mL scale, negligible pressure at filter inlet (0.2 psi) with no increase, indicating minimal fouling.
- » With 1,800cm² filter at 40L scale, inlet pressure remained below 0.3 psi and profile was comparable to 250mL, confirming suitable filter size.

Centrifugal Pump Scale-Up



Conclusions

- » MeiraGTx's optimized perfusion platform was successfully scaled up from bench-scale to the 40L manufacturing scale, demonstrating a scalable perfusion process.
- » Process efficiency was maintained through the translation of key process parameters from the 250mL scale to the 40L scale.
- » VG titre and cell specific VG titre was maintained between scales.
- » Critical quality attributes at the 40L scale were shown to be consistent with the bench-scale process.
- » Residual DNA levels were maintained at an adequate level for patient safety across production scales.



- » VG titre and cell specific VG titre at the 40L manufacturing scale was in line with the 250mL bench scale.
- » AAV produced with a scaled-up 40L perfusion process maintained high product quality, equivalent to the 250mL scale.